Genomic Vision SA is a leading company that focuses on the development of innovative genomic solutions. With a strong commitment to the advancement of genetic research, the company values excellence, collaboration, and integrity. Genomic Vision SA follows a corporate philosophy aimed at improving human health through cutting-edge technology and accurate genetic analyses. By leveraging their expertise in molecular combing and genomic profiling, Genomic Vision SA is dedicated to providing reliable and efficient diagnostic solutions for various genetic diseases. With its emphasis on progress and scientific excellence, Genomic Vision SA strives to contribute to the betterment of healthcare and the understanding of human genetics.

Genomic Vision SA is primarily present in various countries and regions across the world. With its headquarters in France, the company has a strong presence in Europe, including countries like Germany, the United Kingdom, Spain, Italy, and Switzerland. Additionally, Genomic Vision SA has established significant operations and partnerships in North America, particularly in the United States and Canada. The company also has a growing presence in Asia, with a focus on countries like China, Japan, and South Korea. Genomic Vision SA's global reach showcases its commitment to expanding its innovative genomic analysis solutions worldwide.

Genomic Vision SA has achieved several significant milestones in its history. One notable achievement is the development of the proprietary Molecular Combing technology, which enables the direct visualization and analysis of single DNA molecules. This groundbreaking innovation has positioned Genomic Vision SA as a leader in genetic testing and diagnostics. Additionally, the company has successfully collaborated with renowned research institutions and industry partners to validate its technology and expand its applications in various fields, including cancer research, rare genetic diseases, and agrigenomics. With its continuous efforts in advancing genomic medicine, Genomic Vision SA is making notable contributions to the field of molecular diagnostics.

Genomic Vision SA is a leading biotechnology company specializing in molecular diagnostics and analysis of genetic diseases. Founded in 2004 and headquartered in France, Genomic Vision aims to revolutionize genetic testing through its innovative molecular combing technology. This technique enables the direct visualization and study of the genome structure, allowing for the identification of genetic abnormalities and the development of personalized medicine. Genomic Vision has also established strategic partnerships with renowned institutions and industry leaders to further advance its proprietary technology. With its dedication to driving precision medicine, Genomic Vision SA continues to make significant contributions to the field of genomics and enhance the lives of patients worldwide.

The main competitors of Genomic Vision SA in the market include companies such as Illumina, Inc., Thermo Fisher Scientific Inc., Pacific Biosciences of California, Inc., and Bionano Genomics, Inc. These companies operate in the field of genomics and offer technologies and solutions related to genetic analysis and molecular diagnostics. They compete with Genomic Vision SA in terms of developing innovative genomic platforms, products, and services to cater to the needs of various industries, including healthcare, pharmaceuticals, research institutions, and more.

Genomic Vision SA is primarily active in the biotechnology and healthcare industries.

The business model of Genomic Vision SA revolves around developing and commercializing innovative molecular diagnostic solutions for genetic diseases and cancer. Their proprietary technology, known as molecular combing, allows for the identification and analysis of genetic abnormalities with high precision and sensitivity. By partnering with pharmaceutical and biotech companies, Genomic Vision SA aims to provide personalized and reliable diagnostics that can guide treatment decisions and enable targeted therapies. This business model positions Genomic Vision SA as a leader in the field of molecular diagnostics, offering valuable insights into the understanding, prevention, and management of genetic disorders and oncology.

KGV за Genomic Vision в момента не може да бъде изчислено.

KUV за Genomic Vision в момента не може да бъде изчислено.

AlleAktien качественият резултат за Genomic Vision е 6/10.

Приходите не могат да бъдат изчислени в момента за Genomic Vision.

Печалбата за Genomic Vision в момента не може да бъде изчислена.

Genomic Vision SA is a French biotechnology company specializing in the development and commercialization of molecular genetic solutions for research, diagnosis, and treatment of genetic diseases. The company was founded in 2004 and has its headquarters in Bagneux, France.

Genomic Vision разпределя дивидента от 0 EUR на плащания годишно.

Дивидентата за Genomic Vision в момента не може да бъде изчислена или компанията не разпределя дивиденти.

ISIN на Genomic Vision е FR0011799907.

WKN на Genomic Vision е A110TM.

Тикерът на Genomic Vision е GV.PA.

През последните 12 месеца Genomic Vision изплати дивиденда в размер на . Това съответства на дивидендна доходност от около . За следващите 12 месеца се очаква Genomic Vision да изплати дивиденда в размер на 0 EUR.

Дивидентната доходност на Genomic Vision в момента е .

Genomic Vision изплаща дивидент на тримесечие. Той се разпределя в месеците .

Genomic Vision платеше дивиденда всяка година през последните 0 години.

За идните 12 месеца се очакват дивиденти в размер на 0 EUR. Това съответства на дивидентна доходност от 0 %.

Genomic Vision се отнася за сектор 'Здраве'.

За да получите последното дивидентно плащане от Genomic Vision на 9.09.2024 г. в размер на 0 EUR, трябваше да притежавате акцията в портфейла си преди Ex-деня на 9.09.2024 г..

Последното дивидентно плащане беше извършено на 9.09.2024 г..

През година 2023 Genomic Vision изплати 0 EUR под формата на дивиденти.

Дивидентите от Genomic Vision се изплащат в EUR.